(Q39466467)

12 September 2017

title

Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma (English)

1 reference

12 September 2017

1

1 reference

12 September 2017

2

1 reference

12 September 2017

Armando Santoro

4

1 reference

ORCID Public Data File 2021

author name string

Matteo Simonelli

series ordinal

3

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

12 September 2017

1 reference

12 September 2017

volume

9

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

153-165

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Invasive growth: a MET-driven genetic programme for cancer and stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.188

21 January 2018

Identifiers

DOI

10.2217/FON.12.188

1 reference

12 September 2017

1 reference